Jones Financial Companies
SMMT icon

Jones Financial Companies’s Summit Therapeutics SMMT Stock Holding History

Jones Financial Companies’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1K Buy
3,859
+2,823
+272% +$50.1K ﹤0.01% 3097
2026
Q1 		$17.2K Buy
1,036
+488
+89% +$7.89K ﹤0.01% 3349
2025
Q4 		$9.59K Buy
548
+114
+26% +$2.15K ﹤0.01% 3235
2025
Q3 		$9.09K Buy
434
+21
+5% +$509 ﹤0.01% 3117
2025
Q2 		$8.51K Hold
413
– – ﹤0.01% 2933
2025
Q1 		$8.39K Sell
413
-13
-3% -$261 ﹤0.01% 2780
2024
Q4 		$7.6K Buy
426
+386
+965% +$7.48K ﹤0.01% 2627
2024
Q3 		$835 Buy
+40
New +$559 ﹤0.01% 2838

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jones Financial Companies's SMMT Position: Q2 2026 in Review

Jones Financial Companies increased its Summit Therapeutics (SMMT) stake by 272% in Q2 2026, buying an estimated $50.1K and bringing the position to 3,859 shares worth $54.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3097.

Jones Financial Companies first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Jones Financial Companies held 3,859 shares of Summit Therapeutics worth $54.1K as of Q2 2026.
  • Jones Financial Companies bought 2,823 Summit Therapeutics shares in Q2 2026, an estimated $50.1K.
  • Summit Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3097 holding.
  • Jones Financial Companies first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.